Mesoblast Past Earnings Performance

Past criteria checks 0/6

Mesoblast has been growing earnings at an average annual rate of 0.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 30.6% per year.

Key information

0.5%

Earnings growth rate

11.9%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-30.6%
Return on equity	-18.3%
Net Margin	-1,490.3%
Last Earnings Update	30 Jun 2024

Recent past performance updates

No updates

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Revenue & Expenses Breakdown

How Mesoblast makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:MESO Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	6	-88	24	0
31 Mar 24	7	-82	23	0
31 Dec 23	7	-73	24	0
30 Sep 23	8	-81	24	0
30 Jun 23	8	-82	25	0
31 Mar 23	8	-81	26	0
31 Dec 22	8	-84	27	0
30 Sep 22	8	-86	28	0
30 Jun 22	10	-91	27	0
31 Mar 22	10	-92	28	0
31 Dec 21	10	-97	29	0
30 Sep 21	10	-97	29	0
30 Jun 21	7	-99	31	0
31 Mar 21	6	-109	31	0
31 Dec 20	16	-98	29	0
30 Sep 20	16	-97	28	-12
30 Jun 20	32	-78	26	0
31 Mar 20	33	-66	24	-48
31 Dec 19	22	-76	23	-34
30 Sep 19	22	-76	21	-6
30 Jun 19	17	-90	22	0
31 Mar 19	16	-90	21	66
31 Dec 18	16	-86	22	68
30 Sep 18	28	-48	23	69
30 Jun 18	17	-35	22	0
31 Mar 18	16	-42	24	64
31 Dec 17	16	-30	23	61
30 Sep 17	3	-64	23	60
30 Jun 17	2	-77	23	59
31 Mar 17	29	-1	22	57
31 Dec 16	32	-8	22	55
30 Sep 16	35	-11	22	53
30 Jun 16	43	-4	23	50
31 Mar 16	20	-83	25	54
31 Dec 15	20	-88	26	56
30 Sep 15	20	-94	28	61
30 Jun 15	20	-96	30	63
31 Mar 15	21	-85	26	56
31 Dec 14	24	-84	25	55
30 Sep 14	26	-75	24	51
30 Jun 14	23	-76	24	51
31 Mar 14	30	-68	23	49
31 Dec 13	35	-58	21	46

Quality Earnings: MESO is currently unprofitable.

Growing Profit Margin: MESO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MESO is unprofitable, but has reduced losses over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare MESO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MESO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: MESO has a negative Return on Equity (-18.31%), as it is currently unprofitable.

Mesoblast Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L

Mesoblast EPS beats by $0.22, misses on revenue

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited

Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline

Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited

Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application

Mesoblast Limited Announces Updates on RYONCIL

Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Auditor Raises 'Going Concern' Doubt

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.33959 million.

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity